ByeAcne/Demographic
Acne Treatment for Dark Skin Tones — Expert Care That Understands Your Skin
Acne in darker skin tones carries a higher risk of post-inflammatory hyperpigmentation and keloid scarring. Get prescription treatment that addresses both the acne and these unique risks.
Reviewed by a licensed physician · Updated May 2026
Acne Treatment has historically underserved patients with darker skin tones, both in clinical training (darker skin is underrepresented in medical education materials) and in research (most acne drug trials have historically enrolled predominantly lighter-skinned populations). ByeAcne physicians are trained to recognize and address the specific needs of patients across all Fitzpatrick skin types.
For patients with skin tones IV through VI, post-inflammatory hyperpigmentation is frequently the primary concern — the dark spots left after acne heals can be darker, larger, and more persistent than the original pimple, and can take 6-12 months to fully fade without treatment. Building PIH prevention and treatment into the acne prescription from the start, rather than addressing it as an afterthought, dramatically improves outcomes for darker-skinned patients.
Azelaic acid deserves special emphasis here. Its dual action against C. acnes bacteria and tyrosinase activity makes it uniquely well-suited for darker-skinned acne patients who need both effective acne treatment and meaningful PIH prevention. Your ByeAcne physician will consider azelaic acid as a core component of your treatment if you have Fitzpatrick types IV or above.
Why PIH behaves differently in darker skin
Melanocytes in Fitzpatrick IV–VI skin produce more melanin at baseline and respond more vigorously to inflammation. When an acne lesion heals, the surrounding melanocytes release excess melanin into the skin — sometimes into the dermis, where it can take 6–18 months to fade. This post-inflammatory hyperpigmentation (PIH) is often the most visible long-term consequence of acne in darker skin. Patients may describe it as "my acne leaves dark marks that are worse than the pimples themselves," and clinically, that description is accurate.
Because PIH severity correlates with both the duration and intensity of inflammation, aggressive early treatment is the most effective PIH prevention strategy. Every week of active inflammatory acne in darker skin means another round of PIH that will take months to fade. Getting inflammation under control quickly — with an oral antibiotic for severe cases, topical anti-inflammatories for mild-to-moderate cases, and aggressive sun protection throughout — shortens the cumulative PIH burden dramatically.
Treatment selection also shifts. Azelaic acid becomes a core medication rather than a secondary option because it simultaneously treats acne and inhibits tyrosinase, the enzyme responsible for melanin production. Tretinoin is equally important but used at lower concentrations initially to avoid retinoid-induced inflammation that would paradoxically worsen PIH in this population. Keloid risk — especially on the chest, shoulders, and back — is also considered, with more conservative prescribing for patients with keloidal history.
Treatment options a doctor may consider
- Azelaic acid 15–20%
Core medication for dark-skin acne. Treats acne and fades PIH simultaneously by inhibiting tyrosinase. Twice-daily application. Safe across all Fitzpatrick types including during pregnancy.
- Topical tretinoin (0.025% starting)
Start low and titrate slowly. Irritation drives PIH in dark skin; aggressive retinoid protocols often backfire. Paired with ceramide moisturizer to buffer.
- Oral doxycycline for moderate-severe inflammatory acne
Rapidly reduces inflammation, which is the best PIH-prevention strategy available. 3–4 month course paired with topical regimen.
- Daily mineral SPF 50+
Non-negotiable. UV exposure deepens existing PIH and triggers new PIH from even minor inflammation. Mineral (zinc oxide/titanium dioxide) sunscreens preferred. Tinted versions available to avoid white cast.
- PIH-focused adjuncts after acne is controlled
Once active acne is resolved, additional PIH-fading agents (topical hydroquinone short courses, niacinamide, kojic acid) can accelerate clearance of existing marks. Prescribed only after inflammation is under control.
Your specific regimen depends on your medical history, current medications, and intake photos. Only your physician can determine what's appropriate.
Who is the ideal candidate for this protocol
Patients with Fitzpatrick IV, V, or VI skin (darker tan, brown, dark brown) whose primary concern alongside active acne is the dark marks left behind. Patients of African, Caribbean, South Asian, Middle Eastern, Latino, Pacific Islander, Native American, or East Asian ancestry whose skin tone places them at higher PIH risk. Patients whose "acne" has largely resolved but left extensive residual hyperpigmentation that is still visible months after the original lesions healed. Not the best fit for patients with active keloidal scarring patterns that need in-person procedural evaluation, those with melasma (different pigmentation pathway requiring different treatment), or anyone whose "dark marks" are actually raised hypertrophic scars or keloids.